Individualising care – considerations in the escalation of pharmacological management of type 2 diabetes - QI&CPD - Category 2
Attaining optimal blood glucose management in patients with type 2 diabetes is important to improve both short-term and long-term health outcomes. A sustained legacy effect of intensive glucose-management in type 2 diabetes has been observed, indicating a continued reduction in microvascular risk. In addition, the legacy effect demonstrates an association between intensive glucose management and a significantly decreased risk of myocardial infarction and death.A general glycaemic target of HbA1c = 7% (53mmol/mol) has therefore been recommended for newly diagnosed and uncomplicated patients. Over 60% of patients, however, are reported as not achieving their glycaemic goals. One Australian study showed less than half of patients with type 2 diabetes seen in general practice had an HbA1c = 7% (53 mmol/mol) with 25% having an HbA1c > 8% (64mmol/mol). Current glycaemic management seems to be “missing the target” of accepted treatment goals.
This activity has been approved by The Royal Australian College of General Practitioners QI&CPD Program. Total Points: 4 Point(s) (Category 2)
John Eric Barlow
MBBS, MRACGP
Clinical Supervisor, University of Notre Dame, NSW
Surgical Assistant Strathfield Private Hospital, NSW
Westmead Private Hospital, NSW
Rachel Freeman
APD, CDE, BHSc (Nut&Diet), MSc (Diabetes)
Professional Services Manager
Australian Diabetes Educators Association
On completion of this program, participants will be better able to:
- Explain the rationale behind timely and effective treatment escalation in type 2 diabetes
- Identify and assess GP and patient factors contributing to treatment inertia
- Individualise glycaemic targets according to clinical factors and patient circumstances
- Navigate second-line treatment options for type 2 diabetes to select appropriate therapies according to each individual’s clinical needs and circumstances